To evaluate the relationships between the serum concentration of Erlotinib and the effects and toxicities of them
Not Applicable
Recruiting
- Conditions
- non-squamous non-small cell lung cancer
- Registration Number
- JPRN-UMIN000012831
- Lead Sponsor
- agasaki Thoracic Oncology Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1) severe cardiac effusion 2) severe SVC syndrome 3) severe complications 4) severe cardiac diseases 5) severe diabetes mellitus or hypertension 6) severe infections 7) Interstitial pneumonia or pulmonary fibrosis on chest CT scans 8)history of drug allergy 9)pregnant or or lactating women or those who declined contraception 10)those judged not suitable by the attending physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method